Tavolimab - MedImmune

Drug Profile

Tavolimab - MedImmune

Alternative Names: MEDI-0562; Tavolixizumab

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer European Network of Gynaecological Oncological Trial Groups; MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 06 Feb 2018 Tavolimab is still in phase I trials for Solid tumours (Second-line therapy or greater, Late-stage disease, Monotherapy) in USA (NCT02318394)
  • 02 Feb 2018 Phase-II clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in Denmark (unspecified route) (NCT03267589)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top